Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy

被引：3

作者：

Inoue, Yusuke ^{[1
]}

Inui, Naoki ^{[1
,2
]}

机构：

[1] Hamamatsu Univ Sch Med, Div 2, Dept Internal Med, Hamamatsu, Japan

[2] Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, Hamamatsu, Japan

来源：

INTERNAL MEDICINE | 2024年

关键词：

immune-related adverse event; irAE; immune checkpoint inhibitor; efficacy; prognosis; ACUTE KIDNEY INJURY; CELL LUNG-CANCER; ADRENAL INSUFFICIENCY; THYROID-DYSFUNCTION; RISK-FACTORS; NIVOLUMAB; MELANOMA; IMMUNOTHERAPY; EFFICACY; PEMBROLIZUMAB;

D O I：

10.2169/internalmedicine.4654-24

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The number of patients with cancer qualifying for treatment with immune checkpoint inhibitors (ICIs) continues to increase, and a clearer understanding of the mechanisms underlying their activity-driven side effects or immune-related adverse events (irAEs) has become crucial. Patients receiving ICIs can develop irAEs in any organ, and numerous studies have suggested that irAE development may be associated with improved ICI efficacy. However, the robustness and magnitude of such associations are unclear, and little is known about the relationship between irAE development and ICI efficacy at the individual organ level. A precise understanding of these links could improve patient care and provide further insight into the immunological mechanisms underlying both irAE development and ICI efficacy. We herein review the prognostic implications of irAEs occurring in patients with cancer treated with ICIs and discuss outstanding issues that should be addressed in future studies.

引用

页数：17

共 154 条

[1] Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice [J].

Ahn, Beung-Chul ;

Pyo, Kyoung-Ho ;

Xin, Chun-Feng ;

Jung, Dongmin ;

Shim, Hyo Sup ;

Lee, Chang Young ;

Park, Seong Yong ;

Yoon, Hong In ;

Hong, Min Hee ;

Cho, Byoung Chul ;

Kim, Hye Ryun .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (06) :1613-1623

[2] Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors [J].

Aldrich, Jeffrey ;

Pundole, Xerxes ;

Tummala, Sudhakar ;

Palaskas, Nicolas ;

Andersen, Clark R. ;

Shoukier, Mahran ;

Abdel-Wahab, Noha ;

Deswal, Anita ;

Suarez-Almazor, Maria E. .

ARTHRITIS & RHEUMATOLOGY, 2021, 73 (05) :885-895

[3] Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies [J].

Amoroso, V. ;

Gallo, F. ;

Alberti, A. ;

Paloschi, D. ;

Bravo, W. Ferrari ;

Esposito, A. ;

Cosentini, D. ;

Grisanti, S. ;

Pedersini, R. ;

Petrelli, F. ;

Berruti, A. .

ESMO OPEN, 2023, 8 (02)

[4] Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution [J].

Anquetil, Celine ;

Salem, Joe-Elie ;

Lebrun-Vignes, Benedicte ;

Johnson, Douglas B. ;

Mammen, Andrew L. ;

Stenzel, Werner ;

Leonard-Louis, Sarah ;

Benveniste, Olivier ;

Moslehi, Javid J. ;

Allenbach, Yves .

CIRCULATION, 2018, 138 (07) :743-745

[5] Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort [J].

Ascierto, Paolo A. ;

Simeone, Ester ;

Sileni, Vanna Chiarion ;

Pigozzo, Jacopo ;

Maio, Michele ;

Altomonte, Maresa ;

Del Vecchio, Michele ;

Di Guardo, Lorenza ;

Marchetti, Paolo ;

Ridolfi, Ruggero ;

Cognetti, Francesco ;

Testori, Alessandro ;

Bernengo, Maria Grazia ;

Guida, Michele ;

Marconcini, Riccardo ;

Mandala, Mario ;

Cimminiello, Carolina ;

Rinaldi, Gaetana ;

Aglietta, Massimo ;

Queirolo, Paola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[6] Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer [J].

Aso, Mari ;

Toi, Yukihiro ;

Sugisaka, Jun ;

Aiba, Tomoiki ;

Kawana, Sachiko ;

Saito, Ryohei ;

Ogasawara, Takahiro ;

Tsurumi, Kyoji ;

Ono, Kana ;

Shimizu, Hisashi ;

Domeki, Yutaka ;

Terayama, Keisuke ;

Kawashima, Yosuke ;

Nakamura, Atsushi ;

Yamanda, Shinsuke ;

Kimura, Yuichiro ;

Honda, Yoshihiro ;

Sugawara, Shunichi .

ONCOLOGIST, 2020, 25 (03) :E536-E544

[7] Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina [J].

Atchley, William T. ;

Alvarez, Carolina ;

Saxena-Beem, Shruti ;

Schwartz, Todd A. ;

Ishizawar, Rumey C. ;

Patel, Kunal P. ;

Rivera, M. Patricia .

CHEST, 2021, 160 (02) :731-742

[8] Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients [J].

Baek, Han-Sang ;

Jeong, Chaiho ;

Shin, Kabsoo ;

Lee, Jaejun ;

Suh, Heysun ;

Lim, Dong-Jun ;

Kang, Moo Il ;

Ha, Jeonghoon .

BMC ENDOCRINE DISORDERS, 2022, 22 (01)

[9] Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy [J].

Baker, Megan L. ;

Yamamoto, Yu ;

Perazella, Mark A. ;

Dizman, Nazli ;

Shirali, Anushree C. ;

Hafez, Navid ;

Weinstein, Jason ;

Simonov, Michael ;

Testani, Jeffrey M. ;

Kluger, Harriet M. ;

Cantley, Lloyd G. ;

Parikh, Chirag R. ;

Wilson, F. Perry ;

Moledina, Dennis G. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)

[10] Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study [J].

Bao, Zhiyao ;

Luo, Lifeng ;

Xu, Tian ;

Yang, Jin ;

Lv, Mengchen ;

Ni, Lei ;

Sun, Xianwen ;

Chen, Wei ;

Zhou, Lin ;

Wang, Xiaofei ;

Xiang, Yi ;

Gao, Beili .

ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)

← 1 2 3 4 5 6 7 8 9 10 →